ID   MK03_HUMAN              Reviewed;         379 AA.
AC   P27361; A8CZ58; B0LPG3; Q8NHX1;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   12-OCT-2022, entry version 240.
DE   RecName: Full=Mitogen-activated protein kinase 3;
DE            Short=MAP kinase 3;
DE            Short=MAPK 3;
DE            EC=2.7.11.24;
DE   AltName: Full=ERT2;
DE   AltName: Full=Extracellular signal-regulated kinase 1;
DE            Short=ERK-1;
DE   AltName: Full=Insulin-stimulated MAP2 kinase;
DE   AltName: Full=MAP kinase isoform p44;
DE            Short=p44-MAPK;
DE   AltName: Full=Microtubule-associated protein 2 kinase;
DE   AltName: Full=p44-ERK1;
GN   Name=MAPK3; Synonyms=ERK1, PRKM3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hepatoma;
RX   PubMed=7687743; DOI=10.1128/mcb.13.8.4679-4690.1993;
RA   Charest D.L., Jirik F., Harder K., Pelech S.L., Mordret G.;
RT   "Molecular cloning, expression, and characterization of the human mitogen-
RT   activated protein kinase p44erk1.";
RL   Mol. Cell. Biol. 13:4679-4690(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Aebersold D.M., Yung Y., Seger R.;
RT   "Properties of human ERK1b.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Cheng H., Ren S., Qiu R., Wang M., Feng Y.H.;
RT   "Identification of dominant negative Erk1/2 variants in cancer cells.";
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-15; 33-41; 88-94; 117-131; 212-220; 279-287; 303-318
RP   AND 360-370, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Dhillon A.S., Kolch W.;
RL   Submitted (FEB-2008) to UniProtKB.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 14-379 (ISOFORM 1).
RX   PubMed=1540184; DOI=10.1016/0006-291x(92)91891-s;
RA   Owaki H., Makar R., Boulton T.G., Cobb M.H., Geppert T.D.;
RT   "Extracellular signal-regulated kinases in T cells: characterization of
RT   human ERK1 and ERK2 cDNAs.";
RL   Biochem. Biophys. Res. Commun. 182:1416-1422(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 25-379 (ISOFORM 1).
RX   PubMed=1319925; DOI=10.1016/0014-5793(92)80612-k;
RA   Gonzalez F.A., Raden D.L., Rigby M.R., Davis R.J.;
RT   "Heterogeneous expression of four MAP kinase isoforms in human tissues.";
RL   FEBS Lett. 304:170-178(1992).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF STMN1.
RX   PubMed=8325880; DOI=10.1016/s0021-9258(18)82435-8;
RA   Marklund U., Brattsand G., Shingler V., Gullberg M.;
RT   "Serine 25 of oncoprotein 18 is a major cytosolic target for the mitogen-
RT   activated protein kinase.";
RL   J. Biol. Chem. 268:15039-15047(1993).
RN   [12]
RP   INTERACTION WITH HIV-1 NEF (MICROBIAL INFECTION).
RX   PubMed=8794306; DOI=10.1128/jvi.70.10.6701-6708.1996;
RA   Greenway A.L., Azad A., Mills J., McPhee D.A.;
RT   "Human immunodeficiency virus type 1 Nef binds directly to LCK and mitogen-
RT   activated protein kinase, inhibiting kinase activity.";
RL   J. Virol. 70:6701-6708(1996).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF MKNK1/MNK1.
RX   PubMed=9155018; DOI=10.1093/emboj/16.8.1921;
RA   Fukunaga R., Hunter T.;
RT   "MNK1, a new MAP kinase-activated protein kinase, isolated by a novel
RT   expression screening method for identifying protein kinase substrates.";
RL   EMBO J. 16:1921-1933(1997).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF MAPKAPK5.
RX   PubMed=9480836; DOI=10.1006/bbrc.1998.8135;
RA   Ni H., Wang X.S., Diener K., Yao Z.;
RT   "MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated
RT   protein kinase, is a substrate of the extracellular-regulated kinase (ERK)
RT   and p38 kinase.";
RL   Biochem. Biophys. Res. Commun. 243:492-496(1998).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF CANX, AND INTERACTION WITH CANX.
RX   PubMed=10393181; DOI=10.1093/emboj/18.13.3655;
RA   Chevet E., Wong H.N., Gerber D., Cochet C., Fazel A., Cameron P.H.,
RA   Gushue J.N., Thomas D.Y., Bergeron J.J.;
RT   "Phosphorylation by CK2 and MAPK enhances calnexin association with
RT   ribosomes.";
RL   EMBO J. 18:3655-3666(1999).
RN   [16]
RP   DEPHOSPHORYLATION BY DUSP3.
RX   PubMed=10224087; DOI=10.1074/jbc.274.19.13271;
RA   Todd J.L., Tanner K.G., Denu J.M.;
RT   "Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates
RT   for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in
RT   down-regulating the ERK pathway.";
RL   J. Biol. Chem. 274:13271-13280(1999).
RN   [17]
RP   SUBCELLULAR LOCATION, INTERACTION WITH MAP2K1/MEK1, AND DOMAIN.
RX   PubMed=10521408; DOI=10.1074/jbc.274.43.30349;
RA   Rubinfeld H., Hanoch T., Seger R.;
RT   "Identification of a cytoplasmic-retention sequence in ERK2.";
RL   J. Biol. Chem. 274:30349-30352(1999).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF DUSP1.
RX   PubMed=10617468; DOI=10.1126/science.286.5449.2514;
RA   Brondello J.M., Pouyssegur J., McKenzie F.R.;
RT   "Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent
RT   phosphorylation.";
RL   Science 286:2514-2517(1999).
RN   [19]
RP   INTERACTION WITH HSF1.
RX   PubMed=10747973; DOI=10.1074/jbc.m000958200;
RA   Dai R., Frejtag W., He B., Zhang Y., Mivechi N.F.;
RT   "c-Jun NH2-terminal kinase targeting and phosphorylation of heat shock
RT   factor-1 suppress its transcriptional activity.";
RL   J. Biol. Chem. 275:18210-18218(2000).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF IER3, INTERACTION WITH IER3, AND ACTIVITY
RP   REGULATION.
RX   PubMed=12356731; DOI=10.1093/emboj/cdf488;
RA   Garcia J., Ye Y., Arranz V., Letourneux C., Pezeron G., Porteu F.;
RT   "IEX-1: a new ERK substrate involved in both ERK survival activity and ERK
RT   activation.";
RL   EMBO J. 21:5151-5163(2002).
RN   [21]
RP   INTERACTION WITH NISCH.
RX   PubMed=11912194; DOI=10.1074/jbc.m111838200;
RA   Sano H., Liu S.C.H., Lane W.S., Piletz J.E., Lienhard G.E.;
RT   "Insulin receptor substrate 4 associates with the protein IRAS.";
RL   J. Biol. Chem. 277:19439-19447(2002).
RN   [22]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF GRB10.
RX   PubMed=15952796; DOI=10.1021/bi050413i;
RA   Langlais P., Wang C., Dong L.Q., Carroll C.A., Weintraub S.T., Liu F.;
RT   "Phosphorylation of Grb10 by mitogen-activated protein kinase:
RT   identification of Ser150 and Ser476 of human Grb10zeta as major
RT   phosphorylation sites.";
RL   Biochemistry 44:8890-8897(2005).
RN   [24]
RP   INTERACTION WITH DAPK1.
RX   PubMed=15616583; DOI=10.1038/sj.emboj.7600510;
RA   Chen C.H., Wang W.J., Kuo J.C., Tsai H.C., Lin J.R., Chang Z.F., Chen R.H.;
RT   "Bidirectional signals transduced by DAPK-ERK interaction promote the
RT   apoptotic effect of DAPK.";
RL   EMBO J. 24:294-304(2005).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF ATF2.
RX   PubMed=12110590; DOI=10.1093/emboj/cdf361;
RA   Ouwens D.M., de Ruiter N.D., van der Zon G.C., Carter A.P., Schouten J.,
RA   van der Burgt C., Kooistra K., Bos J.L., Maassen J.A., van Dam H.;
RT   "Growth factors can activate ATF2 via a two-step mechanism: phosphorylation
RT   of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-
RT   p38.";
RL   EMBO J. 21:3782-3793(2002).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2.
RX   PubMed=12974390; DOI=10.1515/bc.2003.134;
RA   Wu Y., Chen Z., Ullrich A.;
RT   "EGFR and FGFR signaling through FRS2 is subject to negative feedback
RT   control by ERK1/2.";
RL   Biol. Chem. 384:1215-1226(2003).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF BTG2.
RX   PubMed=15788397; DOI=10.1074/jbc.m500318200;
RA   Hong J.W., Ryu M.S., Lim I.K.;
RT   "Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1
RT   binding in cytoplasm and cell death.";
RL   J. Biol. Chem. 280:21256-21263(2005).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH HSF4.
RX   PubMed=16581800; DOI=10.1128/mcb.26.8.3282-3294.2006;
RA   Hu Y., Mivechi N.F.;
RT   "Association and regulation of heat shock transcription factor 4b with both
RT   extracellular signal-regulated kinase mitogen-activated protein kinase and
RT   dual-specificity tyrosine phosphatase DUSP26.";
RL   Mol. Cell. Biol. 26:3282-3294(2006).
RN   [30]
RP   PHOSPHORYLATION.
RX   PubMed=17274988; DOI=10.1016/j.febslet.2007.01.039;
RA   Degoutin J., Vigny M., Gouzi J.Y.;
RT   "ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic
RT   outcomes in PC12 cells differentiation.";
RL   FEBS Lett. 581:727-734(2007).
RN   [31]
RP   INTERACTION WITH ARRB2.
RX   PubMed=18435604; DOI=10.1042/bj20080685;
RA   Xu T.-R., Baillie G.S., Bhari N., Houslay T.M., Pitt A.M., Adams D.R.,
RA   Kolch W., Houslay M.D., Milligan G.;
RT   "Mutations of beta-arrestin 2 that limit self-association also interfere
RT   with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs:
RT   implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs.";
RL   Biochem. J. 413:51-60(2008).
RN   [32]
RP   INTERACTION WITH ADAM15.
RX   PubMed=18296648; DOI=10.1158/1541-7786.mcr-07-2028;
RA   Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M.,
RA   Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C.,
RA   Edwards D.R.;
RT   "Distinct functions of natural ADAM-15 cytoplasmic domain variants in human
RT   mammary carcinoma.";
RL   Mol. Cancer Res. 6:383-394(2008).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [34]
RP   INTERACTION WITH TPR.
RX   PubMed=18794356; DOI=10.1128/mcb.00925-08;
RA   Vomastek T., Iwanicki M.P., Burack W.R., Tiwari D., Kumar D., Parsons J.T.,
RA   Weber M.J., Nandicoori V.K.;
RT   "Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and
RT   docking domain on the nuclear pore complex protein Tpr cooperatively
RT   regulate ERK2-Tpr interaction.";
RL   Mol. Cell. Biol. 28:6954-6966(2008).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND TYR-204, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [37]
RP   FUNCTION IN KIT SIGNALING PATHWAY, AND PHOSPHORYLATION.
RX   PubMed=19265199; DOI=10.1074/jbc.m808058200;
RA   Sun J., Pedersen M., Ronnstrand L.;
RT   "The D816V mutation of c-Kit circumvents a requirement for Src family
RT   kinases in c-Kit signal transduction.";
RL   J. Biol. Chem. 284:11039-11047(2009).
RN   [38]
RP   PHOSPHORYLATION AT TYR-204, AND DEPHOSPHORYLATION AT TYR-204 BY PTPRJ.
RX   PubMed=19494114; DOI=10.1074/jbc.m109.002758;
RA   Sacco F., Tinti M., Palma A., Ferrari E., Nardozza A.P.,
RA   Hooft van Huijsduijnen R., Takahashi T., Castagnoli L., Cesareni G.;
RT   "Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS
RT   pathway by direct dephosphorylation of ERK1/2 kinases.";
RL   J. Biol. Chem. 284:22048-22058(2009).
RN   [39]
RP   INTERACTION WITH SGK1.
RX   PubMed=19447520; DOI=10.1016/j.jhep.2009.02.027;
RA   Won M., Park K.A., Byun H.S., Kim Y.R., Choi B.L., Hong J.H., Park J.,
RA   Seok J.H., Lee Y.H., Cho C.H., Song I.S., Kim Y.K., Shen H.M., Hur G.M.;
RT   "Protein kinase SGK1 enhances MEK/ERK complex formation through the
RT   phosphorylation of ERK2: implication for the positive regulatory role of
RT   SGK1 on the ERK function during liver regeneration.";
RL   J. Hepatol. 51:67-76(2009).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-198, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [41]
RP   PHOSPHORYLATION AT THR-207, ACTIVITY REGULATION, SUBUNIT, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19060905; DOI=10.1038/nm.1893;
RA   Lorenz K., Schmitt J.P., Schmitteckert E.M., Lohse M.J.;
RT   "A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy.";
RL   Nat. Med. 15:75-83(2009).
RN   [42]
RP   REVIEW ON FUNCTION.
RX   PubMed=16393692; DOI=10.1080/02699050500284218;
RA   Yoon S., Seger R.;
RT   "The extracellular signal-regulated kinase: multiple substrates regulate
RT   diverse cellular functions.";
RL   Growth Factors 24:21-44(2006).
RN   [43]
RP   REVIEW ON FUNCTION, AND REVIEW ON SUBCELLULAR LOCATION.
RX   PubMed=19565474; DOI=10.1002/biof.52;
RA   Yao Z., Seger R.;
RT   "The ERK signaling cascade--views from different subcellular
RT   compartments.";
RL   BioFactors 35:407-416(2009).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND TYR-204, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [47]
RP   REVIEW ON ACTIVITY REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=21779493; DOI=10.1177/1947601911407328;
RA   Wortzel I., Seger R.;
RT   "The ERK cascade: distinct functions within various subcellular
RT   organelles.";
RL   Genes Cancer 2:195-209(2011).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND TYR-204, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [49]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [50]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND TYR-204, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [52]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=24825908; DOI=10.1074/jbc.m114.547208;
RA   Cheung C.T., Singh R., Kalra R.S., Kaul S.C., Wadhwa R.;
RT   "Collaborator of ARF (CARF) regulates proliferative fate of human cells by
RT   dose-dependent regulation of DNA damage signaling.";
RL   J. Biol. Chem. 289:18258-18269(2014).
RN   [53]
RP   INTERACTION WITH ZNF263.
RX   PubMed=32051553; DOI=10.1038/s41388-020-1206-7;
RA   Yu Z., Feng J., Wang W., Deng Z., Zhang Y., Xiao L., Wang Z., Liu C.,
RA   Liu Q., Chen S., Wu M.;
RT   "The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma
RT   epigenetically.";
RL   Oncogene 39:3163-3178(2020).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.39 ANGSTROMS), AND PHOSPHORYLATION AT TYR-204.
RX   PubMed=18983981; DOI=10.1016/j.bbrc.2008.10.127;
RA   Kinoshita T., Yoshida I., Nakae S., Okita K., Gouda M., Matsubara M.,
RA   Yokota K., Ishiguro H., Tada T.;
RT   "Crystal structure of human mono-phosphorylated ERK1 at Tyr204.";
RL   Biochem. Biophys. Res. Commun. 377:1123-1127(2008).
RN   [55]
RP   VARIANT [LARGE SCALE ANALYSIS] LYS-323.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential component
CC       of the MAP kinase signal transduction pathway. MAPK1/ERK2 and
CC       MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK
CC       cascade. They participate also in a signaling cascade initiated by
CC       activated KIT and KITLG/SCF. Depending on the cellular context, the
CC       MAPK/ERK cascade mediates diverse biological functions such as cell
CC       growth, adhesion, survival and differentiation through the regulation
CC       of transcription, translation, cytoskeletal rearrangements. The
CC       MAPK/ERK cascade also plays a role in initiation and regulation of
CC       meiosis, mitosis, and postmitotic functions in differentiated cells by
CC       phosphorylating a number of transcription factors. About 160 substrates
CC       have already been discovered for ERKs. Many of these substrates are
CC       localized in the nucleus, and seem to participate in the regulation of
CC       transcription upon stimulation. However, other substrates are found in
CC       the cytosol as well as in other cellular organelles, and those are
CC       responsible for processes such as translation, mitosis and apoptosis.
CC       Moreover, the MAPK/ERK cascade is also involved in the regulation of
CC       the endosomal dynamics, including lysosome processing and endosome
CC       cycling through the perinuclear recycling compartment (PNRC); as well
CC       as in the fragmentation of the Golgi apparatus during mitosis. The
CC       substrates include transcription factors (such as ATF2, BCL6, ELK1,
CC       ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN,
CC       GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such
CC       as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of
CC       translation (such as EIF4EBP1) and a variety of other signaling-related
CC       molecules (like ARHGEF2, FRS2 or GRB10). Protein kinases (such as RAF1,
CC       RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK,
CC       MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or
CC       MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are
CC       other substrates which enable the propagation the MAPK/ERK signal to
CC       additional cytosolic and nuclear targets, thereby extending the
CC       specificity of the cascade. {ECO:0000269|PubMed:10393181,
CC       ECO:0000269|PubMed:10617468, ECO:0000269|PubMed:12110590,
CC       ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:12974390,
CC       ECO:0000269|PubMed:15788397, ECO:0000269|PubMed:15952796,
CC       ECO:0000269|PubMed:16581800, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:8325880, ECO:0000269|PubMed:9155018,
CC       ECO:0000269|PubMed:9480836}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Phosphorylated by MAP2K1/MEK1 and MAP2K2/MEK2 on
CC       Thr-202 and Tyr-204 in response to external stimuli like insulin or
CC       NGF. Both phosphorylations are required for activity. This
CC       phosphorylation causes dramatic conformational changes, which enable
CC       full activation and interaction of MAPK1/ERK2 with its substrates.
CC       Dephosphorylated and inactivated by DUSP3, DUSP6 and DUSP9.
CC       {ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:19060905}.
CC   -!- SUBUNIT: Binds both upstream activators and downstream substrates in
CC       multimolecular complexes. Found in a complex with at least BRAF, HRAS,
CC       MAP2K1/MEK1, MAPK3 and RGS14 (By similarity). Interacts with ADAM15,
CC       ARRB2, CANX, DAPK1 (via death domain), HSF4, IER3, MAP2K1/MEK1, MORG1,
CC       NISCH, and SGK1. Interacts with PEA15 and MKNK2 (By similarity). MKNK2
CC       isoform 1 binding prevents from dephosphorylation and inactivation (By
CC       similarity). Interacts with TPR. Interacts with CDKN2AIP. Interacts
CC       with HSF1 (via D domain and preferentially with hyperphosphorylated
CC       form); this interaction occurs upon heat shock (PubMed:10747973).
CC       Interacts with CAVIN4 (By similarity). Interacts with GIT1; this
CC       interaction is necessary for MAPK3 localization to focal adhesions (By
CC       similarity). Interacts with ZNF263 (PubMed:32051553).
CC       {ECO:0000250|UniProtKB:P21708, ECO:0000250|UniProtKB:Q63844,
CC       ECO:0000269|PubMed:10393181, ECO:0000269|PubMed:10521408,
CC       ECO:0000269|PubMed:10747973, ECO:0000269|PubMed:11912194,
CC       ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:15616583,
CC       ECO:0000269|PubMed:16581800, ECO:0000269|PubMed:18296648,
CC       ECO:0000269|PubMed:18435604, ECO:0000269|PubMed:18794356,
CC       ECO:0000269|PubMed:19060905, ECO:0000269|PubMed:19447520,
CC       ECO:0000269|PubMed:24825908, ECO:0000269|PubMed:32051553}.
CC   -!- SUBUNIT: (Microbial infection) Binds to HIV-1 Nef through its SH3
CC       domain. This interaction inhibits its tyrosine-kinase activity.
CC       {ECO:0000269|PubMed:8794306}.
CC   -!- INTERACTION:
CC       P27361; Q9HCU0: CD248; NbExp=3; IntAct=EBI-73995, EBI-9680942;
CC       P27361; P53355: DAPK1; NbExp=5; IntAct=EBI-73995, EBI-358616;
CC       P27361; P49366: DHPS; NbExp=10; IntAct=EBI-73995, EBI-741925;
CC       P27361; P28562: DUSP1; NbExp=3; IntAct=EBI-73995, EBI-975493;
CC       P27361; Q16828: DUSP6; NbExp=5; IntAct=EBI-73995, EBI-746870;
CC       P27361; P19419: ELK1; NbExp=2; IntAct=EBI-73995, EBI-726632;
CC       P27361; Q49AJ0-4: FAM135B; NbExp=3; IntAct=EBI-73995, EBI-25835236;
CC       P27361; Q96NJ5: KLHL32; NbExp=3; IntAct=EBI-73995, EBI-6426390;
CC       P27361; Q02750: MAP2K1; NbExp=2; IntAct=EBI-73995, EBI-492564;
CC       P27361; Q16539: MAPK14; NbExp=5; IntAct=EBI-73995, EBI-73946;
CC       P27361; P27361: MAPK3; NbExp=2; IntAct=EBI-73995, EBI-73995;
CC       P27361; Q96HT8: MRFAP1L1; NbExp=3; IntAct=EBI-73995, EBI-748896;
CC       P27361; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-73995, EBI-25830200;
CC       P27361; Q9ULW8: PADI3; NbExp=3; IntAct=EBI-73995, EBI-10488185;
CC       P27361; Q15121: PEA15; NbExp=4; IntAct=EBI-73995, EBI-714410;
CC       P27361; P14618-1: PKM; NbExp=3; IntAct=EBI-73995, EBI-4304679;
CC       P27361; Q8N490: PNKD; NbExp=4; IntAct=EBI-73995, EBI-746368;
CC       P27361; P23467: PTPRB; NbExp=2; IntAct=EBI-73995, EBI-1265766;
CC       P27361; Q12913: PTPRJ; NbExp=5; IntAct=EBI-73995, EBI-2264500;
CC       P27361; Q14160: SCRIB; NbExp=2; IntAct=EBI-73995, EBI-357345;
CC       P27361; P13051-2: UNG; NbExp=3; IntAct=EBI-73995, EBI-25834258;
CC       P27361; Q08509: Eps8; Xeno; NbExp=2; IntAct=EBI-73995, EBI-375596;
CC       P27361; Q60793: Klf4; Xeno; NbExp=2; IntAct=EBI-73995, EBI-3043905;
CC       P27361; Q9EPI6: Nsmf; Xeno; NbExp=2; IntAct=EBI-73995, EBI-6899705;
CC       P27361; Q62132: Ptprr; Xeno; NbExp=3; IntAct=EBI-73995, EBI-6954051;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P21708}.
CC       Nucleus. Membrane, caveola {ECO:0000250|UniProtKB:P21708}. Cell
CC       junction, focal adhesion {ECO:0000250|UniProtKB:Q63844}.
CC       Note=Autophosphorylation at Thr-207 promotes nuclear localization
CC       (PubMed:19060905). PEA15-binding redirects the biological outcome of
CC       MAPK3 kinase-signaling by sequestering MAPK3 into the cytoplasm (By
CC       similarity). {ECO:0000250|UniProtKB:Q63844,
CC       ECO:0000269|PubMed:19060905}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P27361-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P27361-2; Sequence=VSP_041906;
CC       Name=3; Synonyms=ERK1b;
CC         IsoId=P27361-3; Sequence=VSP_041907;
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC       {ECO:0000269|PubMed:10521408}.
CC   -!- PTM: Phosphorylated upon KIT and FLT3 signaling (By similarity). Dually
CC       phosphorylated on Thr-202 and Tyr-204, which activates the enzyme.
CC       Ligand-activated ALK induces tyrosine phosphorylation. Dephosphorylated
CC       by PTPRJ at Tyr-204. {ECO:0000250, ECO:0000269|PubMed:17274988,
CC       ECO:0000269|PubMed:18983981, ECO:0000269|PubMed:19060905,
CC       ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:19494114}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAPK3ID425ch16p11.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X60188; CAA42744.1; -; mRNA.
DR   EMBL; AY033607; AAK52329.1; -; mRNA.
DR   EMBL; DQ399291; ABD60302.1; -; mRNA.
DR   EMBL; EU332853; ABY87542.1; -; Genomic_DNA.
DR   EMBL; AC012645; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471238; EAW79912.1; -; Genomic_DNA.
DR   EMBL; CH471238; EAW79915.1; -; Genomic_DNA.
DR   EMBL; BC013992; AAH13992.1; -; mRNA.
DR   EMBL; M84490; AAA36142.1; -; mRNA.
DR   EMBL; Z11696; CAA77754.1; -; mRNA.
DR   CCDS; CCDS10672.1; -. [P27361-1]
DR   CCDS; CCDS42148.1; -. [P27361-2]
DR   CCDS; CCDS42149.1; -. [P27361-3]
DR   PIR; A48082; A48082.
DR   RefSeq; NP_001035145.1; NM_001040056.2. [P27361-3]
DR   RefSeq; NP_001103361.1; NM_001109891.1. [P27361-2]
DR   RefSeq; NP_002737.2; NM_002746.2. [P27361-1]
DR   PDB; 2ZOQ; X-ray; 2.39 A; A/B=1-379.
DR   PDB; 4QTB; X-ray; 1.40 A; A/B=1-379.
DR   PDB; 6GES; X-ray; 2.07 A; A/B=1-379.
DR   PDBsum; 2ZOQ; -.
DR   PDBsum; 4QTB; -.
DR   PDBsum; 6GES; -.
DR   AlphaFoldDB; P27361; -.
DR   SMR; P27361; -.
DR   BioGRID; 111581; 303.
DR   CORUM; P27361; -.
DR   DIP; DIP-30985N; -.
DR   ELM; P27361; -.
DR   IntAct; P27361; 178.
DR   MINT; P27361; -.
DR   STRING; 9606.ENSP00000263025; -.
DR   BindingDB; P27361; -.
DR   ChEMBL; CHEMBL3385; -.
DR   DrugBank; DB04604; 5-iodotubercidin.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB01169; Arsenic trioxide.
DR   DrugBank; DB08862; Cholecystokinin.
DR   DrugBank; DB01017; Minocycline.
DR   DrugBank; DB02733; Purvalanol.
DR   DrugBank; DB06195; Seliciclib.
DR   DrugBank; DB00605; Sulindac.
DR   DrugBank; DB13930; Ulixertinib.
DR   DrugCentral; P27361; -.
DR   GuidetoPHARMACOLOGY; 1494; -.
DR   MoonDB; P27361; Predicted.
DR   iPTMnet; P27361; -.
DR   MetOSite; P27361; -.
DR   PhosphoSitePlus; P27361; -.
DR   BioMuta; MAPK3; -.
DR   DMDM; 232066; -.
DR   CPTAC; CPTAC-1050; -.
DR   CPTAC; CPTAC-1051; -.
DR   CPTAC; CPTAC-1357; -.
DR   CPTAC; CPTAC-1358; -.
DR   CPTAC; CPTAC-1359; -.
DR   CPTAC; CPTAC-1542; -.
DR   CPTAC; CPTAC-880; -.
DR   EPD; P27361; -.
DR   jPOST; P27361; -.
DR   MassIVE; P27361; -.
DR   MaxQB; P27361; -.
DR   PaxDb; P27361; -.
DR   PeptideAtlas; P27361; -.
DR   PRIDE; P27361; -.
DR   ProteomicsDB; 54383; -. [P27361-1]
DR   ProteomicsDB; 54384; -. [P27361-2]
DR   ProteomicsDB; 54385; -. [P27361-3]
DR   Antibodypedia; 1203; 2390 antibodies from 57 providers.
DR   CPTC; P27361; 6 antibodies.
DR   DNASU; 5595; -.
DR   Ensembl; ENST00000263025.9; ENSP00000263025.4; ENSG00000102882.12. [P27361-1]
DR   Ensembl; ENST00000322266.9; ENSP00000327293.5; ENSG00000102882.12. [P27361-2]
DR   Ensembl; ENST00000395199.7; ENSP00000378625.3; ENSG00000102882.12. [P27361-3]
DR   Ensembl; ENST00000395202.5; ENSP00000378628.1; ENSG00000102882.12. [P27361-2]
DR   GeneID; 5595; -.
DR   KEGG; hsa:5595; -.
DR   MANE-Select; ENST00000263025.9; ENSP00000263025.4; NM_002746.3; NP_002737.2.
DR   UCSC; uc002dws.4; human. [P27361-1]
DR   CTD; 5595; -.
DR   DisGeNET; 5595; -.
DR   GeneCards; MAPK3; -.
DR   HGNC; HGNC:6877; MAPK3.
DR   HPA; ENSG00000102882; Low tissue specificity.
DR   MIM; 601795; gene.
DR   neXtProt; NX_P27361; -.
DR   OpenTargets; ENSG00000102882; -.
DR   PharmGKB; PA30622; -.
DR   VEuPathDB; HostDB:ENSG00000102882; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   GeneTree; ENSGT00940000160691; -.
DR   HOGENOM; CLU_000288_181_1_1; -.
DR   InParanoid; P27361; -.
DR   OMA; EIMTFRP; -.
DR   PhylomeDB; P27361; -.
DR   TreeFam; TF105097; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   PathwayCommons; P27361; -.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-112409; RAF-independent MAPK1/3 activation.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-1181150; Signaling by NODAL.
DR   Reactome; R-HSA-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-HSA-1502540; Signaling by Activin.
DR   Reactome; R-HSA-162658; Golgi Cisternae Pericentriolar Stack Reorganization. [P27361-3]
DR   Reactome; R-HSA-170968; Frs2-mediated activation.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-202670; ERKs are inactivated.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-444257; RSK activation.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors.
DR   Reactome; R-HSA-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-73728; RNA Polymerase I Promoter Opening.
DR   Reactome; R-HSA-74749; Signal attenuation.
DR   Reactome; R-HSA-879415; Advanced glycosylation endproduct receptor signaling.
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   Reactome; R-HSA-8939211; ESR-mediated signaling.
DR   Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-9627069; Regulation of the apoptosome activity.
DR   Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling.
DR   Reactome; R-HSA-9635465; Suppression of apoptosis.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9652169; Signaling by MAP2K mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-9725371; Nuclear events stimulated by ALK signaling in cancer.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   SignaLink; P27361; -.
DR   SIGNOR; P27361; -.
DR   BioGRID-ORCS; 5595; 30 hits in 1119 CRISPR screens.
DR   ChiTaRS; MAPK3; human.
DR   EvolutionaryTrace; P27361; -.
DR   GeneWiki; MAPK3; -.
DR   GenomeRNAi; 5595; -.
DR   Pharos; P27361; Tchem.
DR   PRO; PR:P27361; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; P27361; protein.
DR   Bgee; ENSG00000102882; Expressed in right frontal lobe and 196 other tissues.
DR   ExpressionAtlas; P27361; baseline and differential.
DR   Genevisible; P27361; HS.
DR   GO; GO:0005901; C:caveola; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:UniProtKB.
DR   GO; GO:0005769; C:early endosome; TAS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; TAS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:UniProtKB.
DR   GO; GO:0005770; C:late endosome; TAS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; TAS:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0031143; C:pseudopodium; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004707; F:MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IEA:Ensembl.
DR   GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0030509; P:BMP signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0061308; P:cardiac neural crest cell development involved in heart development; IEA:Ensembl.
DR   GO; GO:0051216; P:cartilage development; IEA:Ensembl.
DR   GO; GO:0072584; P:caveolin-mediated endocytosis; TAS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IDA:CAFA.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IMP:CAFA.
DR   GO; GO:1903351; P:cellular response to dopamine; IMP:CAFA.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IMP:CAFA.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006351; P:DNA-templated transcription; IEA:Ensembl.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0060324; P:face development; IEA:Ensembl.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0060425; P:lung morphogenesis; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; NAS:BHF-UCL.
DR   GO; GO:2000657; P:negative regulation of apolipoprotein binding; IEA:Ensembl.
DR   GO; GO:0042473; P:outer ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0031281; P:positive regulation of cyclase activity; IMP:CACAO.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; IGI:ARUK-UCL.
DR   GO; GO:0120041; P:positive regulation of macrophage proliferation; IGI:ARUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:1904417; P:positive regulation of xenophagy; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030641; P:regulation of cellular pH; IEA:Ensembl.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0051090; P:regulation of DNA-binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; TAS:UniProtKB.
DR   GO; GO:0090170; P:regulation of Golgi inheritance; TAS:UniProtKB.
DR   GO; GO:0030278; P:regulation of ossification; IEA:Ensembl.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; TAS:UniProtKB.
DR   GO; GO:0070849; P:response to epidermal growth factor; IDA:UniProtKB.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:CAFA.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0060440; P:trachea formation; IEA:Ensembl.
DR   GO; GO:0098792; P:xenophagy; IEA:Ensembl.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008349; MAPK_ERK1/2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01770; ERK1ERK2MAPK.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell cycle; Cell junction; Cytoplasm; Direct protein sequencing;
KW   Host-virus interaction; Kinase; Membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:22814378"
FT   CHAIN           2..379
FT                   /note="Mitogen-activated protein kinase 3"
FT                   /id="PRO_0000186251"
FT   DOMAIN          42..330
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..26
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           202..204
FT                   /note="TXY"
FT   ACT_SITE        166
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         48..56
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         71
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:22814378"
FT   MOD_RES         198
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         202
FT                   /note="Phosphothreonine; by MAP2K1 and MAP2K2"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         204
FT                   /note="Phosphotyrosine; by MAP2K1 and MAP2K2"
FT                   /evidence="ECO:0000269|PubMed:18983981,
FT                   ECO:0000269|PubMed:19494114, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         207
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:19060905"
FT   VAR_SEQ         259..302
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_041906"
FT   VAR_SEQ         340..379
FT                   /note="PVAEEPFTFAMELDDLPKERLKELIFQETARFQPGVLEAP -> VGQSPAAV
FT                   GLGAGEQGGT (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_041907"
FT   VARIANT         323
FT                   /note="E -> K (in dbSNP:rs55859133)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042253"
FT   CONFLICT        174
FT                   /note="I -> S (in Ref. 1; CAA42744 and 2; AAK52329)"
FT                   /evidence="ECO:0000305"
FT   STRAND          29..31
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   STRAND          34..36
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   TURN            39..41
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   STRAND          42..51
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   STRAND          54..61
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   TURN            62..65
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   STRAND          66..73
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           79..94
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   STRAND          105..107
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   TURN            112..114
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   STRAND          118..122
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   STRAND          126..128
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           129..135
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           140..159
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           169..171
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   STRAND          172..174
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   STRAND          180..182
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           193..195
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           208..210
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           213..215
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   TURN            216..218
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           225..240
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           250..261
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           266..269
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           275..282
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           292..295
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           301..310
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           315..317
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           321..325
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           328..330
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   TURN            331..333
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           336..338
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           350..354
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           357..368
FT                   /evidence="ECO:0007829|PDB:4QTB"
FT   HELIX           369..371
FT                   /evidence="ECO:0007829|PDB:4QTB"
SQ   SEQUENCE   379 AA;  43136 MW;  E6020CE413EC41F7 CRC64;
     MAAAAAQGGG GGEPRRTEGV GPGVPGEVEM VKGQPFDVGP RYTQLQYIGE GAYGMVSSAY
     DHVRKTRVAI KKISPFEHQT YCQRTLREIQ ILLRFRHENV IGIRDILRAS TLEAMRDVYI
     VQDLMETDLY KLLKSQQLSN DHICYFLYQI LRGLKYIHSA NVLHRDLKPS NLLINTTCDL
     KICDFGLARI ADPEHDHTGF LTEYVATRWY RAPEIMLNSK GYTKSIDIWS VGCILAEMLS
     NRPIFPGKHY LDQLNHILGI LGSPSQEDLN CIINMKARNY LQSLPSKTKV AWAKLFPKSD
     SKALDLLDRM LTFNPNKRIT VEEALAHPYL EQYYDPTDEP VAEEPFTFAM ELDDLPKERL
     KELIFQETAR FQPGVLEAP
//
